LGND Q4 2024 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

LGNDLigand Pharmaceuticals Incorporated

$4B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$43M+52.4% YoY

Gross Profit

$40M93.4% margin

Operating Income

-$10M-22.5% margin

Net Income

-$31M-72.6% margin

EPS (Diluted)

$-1.64

QoQ Revenue Growth

-17.4%

Cash Flow

Operating Cash Flow

$28M

Free Cash Flow

$28M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$942M

Total Liabilities

$111M

Stockholders' Equity

$830M

Cash & Equivalents

$72M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$43M	$28M	+52.4%
Gross Profit	$40M	$26M	+51.2%
Operating Income	-$10M	-$3M	-187.0%
Net Income	-$31M	$18M	-270.9%

Revenue Segments

Royalty

$77M42%

Intangible Royalty Assets

$69M37%

Material Sales, Captisol

$25M13%

Financial Royalty Assets

$8M4%

Royalty, Other

$7M4%